# A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

> **NCT06422403** · PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 360 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular
- Gastric Adenocarcinoma
- GastroEsophageal Cancer
- Oesophageal Cancer
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Extended Dosing Interval - A
- **DRUG:** Extended Dosing Interval - B
- **DRUG:** Extended Dosing Interval - C
- **DRUG:** Standard of Care - A
- **DRUG:** Standard of Care - B
- **DRUG:** Standard of Care - C

## Key facts

- **NCT ID:** NCT06422403
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2029-03-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06422403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06422403, "A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06422403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*